A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Latest Information Update: 10 May 2024
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Acronyms MUsT
- Sponsors Incyte Corporation
- 12 Mar 2024 Results assessing patient-reported outcomes (PROs) at Week 8 presented at the American Academy of Dermatology annual Meeting 2024
- 04 Mar 2024 According to an Incyte Corporation media release, company will host an in-person analyst and investor event on Monday, March 11, 2024, from 9:00-10:30 a.m. PT (12:00-1:30 p.m. ET) to discuss the key data presentations at AAD.
- 04 Mar 2024 According to an Incyte Corporation media release, data from this study will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego and will be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.